ArticleClinical and experimental dental research2026
Advanced Platelet-Rich Fibrin in Surgical Management of Medication-Related Osteonecrosis of the Jaw: A Prospective Case Series Study.
Article in Clinical and experimental dental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication-related osteonecrosis of the jaw (MRONJ) is a severe complication associated with antiresorptive or antiangiogenic therapy. Surgical debridement is the mainstay of treatment for moderate to advanced disease, while adjunctive regenerative approaches such as advanced platelet-rich fibrin (A-PRF) may enhance soft tissue healing. This study aimed to evaluate the clinical outcomes of A-PRF as an adjunct to surgical management of MRONJ.
methodsSeventeen patients diagnosed with MRONJ according to AAOMS criteria were prospectively enrolled. All patients underwent surgical removal of necrotic bone followed by placement of A-PRF membranes and tension-free mucosal closure. A-PRF was prepared from autologous venous blood using a low-speed centrifugation protocol. Mean follow-up was 11.6 months. Treatment success was defined as complete mucosal healing without clinical signs of infection or bone exposure.
resultsThe mean age was 60.2 ± 7.8 years; 70.6% were female and 70.6% had cancer-related disease. Stage 2 MRONJ was most prevalent (58.8%). Complete mucosal healing was achieved in 13 patients (76.5%). Four patients (23.5%) showed persistent bone exposure but reported symptomatic improvement.
conclusionAdjunctive use of A-PRF in MRONJ surgery was associated with favorable soft tissue healing and clinical improvement. Larger controlled studies are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.